News

Thank you to all the patients who participated in the trial targetting the use of a ‘dual immunotherapy’ combination—nivolumab and ipilimumab (NIVO+IPI) — in the treatment of liver cancer patients between 2020 to 2021. This innovative treatment has proved to significantly improve survival rates and tumour control compared to current first-line treatments, lenvatinib and sorafenib. Recently it was approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and China's National Medical Products Administration (NMPA) for global use, offering new hope to liver cancer patients worldwide. 

We were delighted to welcome a group of secondary school students from the HKUMed x QMH Summer Attachment Programme at the HKU Phase 1 Clinical Trials Unit on August 7, 2025.

The visit began with an insightful introduction to clinical trials and HKU-CTC, followed by a guided tour of our Phase 1 Unit. The students engaged in discussions and got a glimpse of the day-to-day processes behind clinical research. It was gratifying to see their curiosity and active engagement as they explored the possibilities of a future in medicine.

We are looking forward to nurturing more innovators of tomorrow!

In celebration of the International Clinical Trials Day, a global celebration honoring a Scottish physician James Lind, who launched the first documented clinical trial on scurvy on May 20, 1747, we set up a booth at Queen Mary Hospital this year to showcase the story behind this special occasion, and to raise social awareness on the significance of clinical trials in medical advancement!

Other than the informative posters educating the public on the close association between new drug discovery and clinical trials, we had also prepared thoughtfully-designed souvenirs to interest participants who passed by our booth! One of our Panda Ambassadors, Dr Hong also joined us at the booth to bring more smiles and energy to the event, creating a welcome space for dialogues with all the participants. We hope you have all enjoyed, and look forward to bringing more medical knowledge to you all soon!

Thank you to all the patients who participated in the oral medication study related to Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer (CTC1946) between 2020 and 2023. We have the honor to inform you that the clinical data of the Phase 3 clinical trial has been submitted to the U.S. Food and Drug Administration (FDA) and the oral medication has been approved, paving ways for new treatment targeting breast cancer.

Clinical Research Governance World Conference 2025 was successfully concluded on January 16, 2025. With over 200 on-site and 800 online registrations, the engagement from all these indsutrial experts was what make the event special. It is our honour to have Professor Lo Chung-mau, Secretary for Health of HKSAR, and Professor Max Shen, Vice-President (Research) of The University of Hong Kong, deliver the opening remarks. Their insights set the tone for a productive conference.

We hope to see you all in the our future events again!

We are delighted to welcome a group of secondary school students visiting our HKU Phase 1 Clinical Trials Centre on November 22, 2024. It was an excellent opportunity to enlighten the next generation about the vital role of clinical trials in progressing public health.

The information session also included introduction to the diversified research projects that our Centre has been working on, sparking their interests in the clinical trials industry and research outputs that can benefit the community.

Study Intervention:

Any drug, medical device, medical method, or procedure aimed at treating, alleviating, diagnosing, or preventing diseases or medical conditions.

Adverse Event (AE):

An adverse condition that volunteers encounter during the research process (e.g., discomfort, symptoms of illness), regardless of whether the adverse event was expected or related to the research procedure or products. The research team must document, analyze, and follow up on each adverse event in detail.

The University of Hong Kong (HKU) welcomes the HKSAR Government's announcement today (23 September) on designating its LKS Faculty of Medicine (HKUMed) as the operator of the Greater Bay Area International Clinical Trial Institute (the GBAICTI). Located in the Hong Kong Park of the Hetao Shenzhen–Hong Kong Science and Technology Innovation Co-operation Zone, the GBAICTI is scheduled to begin operations in the fourth quarter of this year, with the aim of becoming an innovative clinical research platform with global influence to attract mainland and multinational pharmaceutical institutions.

Available in Chinese only.

On August 1, 2024, 20 secondary students visited the HKU Phase 1 Clinical Trials as a part of the HKUMedify – Clinical Exposure Programme 2024. Through our introduction of the realistic clinical trials procedure, in-depth tour of the Phase 1 Centre, and their hands-on experience on simulating volunteer recruitment, we believe the session offers remarkable exposure on the importance of volunteer protection, scientific validity and data integrity.